Ovarian transposition and cervical cancer.
Cervical cancer
Fertility preservation
Ovarian function
Ovarian transposition
Pelvic radiotherapy
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
31
10
2020
accepted:
31
01
2021
pubmed:
16
3
2021
medline:
24
8
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Cervical cancer is the fourth most common female malignancy worldwide. As the focus of treatment is shifting towards balancing oncological outcomes with reproductive benefit, women are becoming increasingly aware of their fertility options. Cervical cancer is one of the primary malignancies where transposition of the ovaries may be indicated. Ovarian transposition should be performed in pre-menopausal women, undergoing pelvic irradiation to preserve ovarian function and prevent early menopause. The review discusses the available literature and synthesises a concise summary for gynaecologic oncology surgeons to counsel affected women. The paradoxical controversy, leading to its under use is acknowledged, due to the scarcity of published data with regard to functional outcomes, and the lack of clinical trials. In cervical cancer, ovarian transposition remains a safe fertility preservation (FP) option, which is associated with high ovarian function preservation, an acceptable rate of ovarian cysts and a negligible risk for metastases in the transposed ovaries.
Identifiants
pubmed: 33715965
pii: S1521-6934(21)00037-7
doi: 10.1016/j.bpobgyn.2021.01.013
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-53Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare no conflicts of interest.